logo
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Business Wire08-05-2025

LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. ('Myriad' or the 'Company') (NASDAQ: MYGN) on behalf of investors concerning the Company's possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On May 6, 2025, Myriad released its first quarter 2025 financial results, revealing 'revenue of $196 million declined by 3% year-over-year' and 'pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.' Additionally, the Company announced reduced financial guidance for 2025 'reflecting first quarter 2025 results and the current business outlook.'
On this news, Myriad's stock price fell $3.00, or 41.3%, to close at $4.27 per share on May 7, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Myriad securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis
Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis

Yahoo

time29 minutes ago

  • Yahoo

Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis

BLACK RIVER FALLS, Wis., June 11, 2025--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the "Company"), a leading civil, building and specialty construction company, announced today that its subsidiary, Lunda Construction Company, has been awarded a contract by the Minnesota Department of Transportation valued at approximately $67.2 million for the I-94 and I-394 Interchange Project in Minneapolis. The scope of work includes repairing 34 bridges and ramps along I-394 and I-94 between downtown Minneapolis and Highway 100. The project also includes maintenance work on the Dunwoody Boulevard ramp, replacing the deck for the Penn Avenue bridge that crosses over I-394, and other improvements along I-394 between downtown Minneapolis and Highway 100. Work is expected to begin in July 2025 with substantial completion anticipated in the summer of 2027. The contract value has been added to the Company's backlog in the second quarter of 2025. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection. View source version on Contacts Tutor Perini CorporationJorge Casado, 818-362-8391Senior Vice President, Investor Relations and Corporate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Yahoo

time29 minutes ago

  • Yahoo

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.

Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Presents New Data on the Benefits of ALYFTREK

Yahoo

time29 minutes ago

  • Yahoo

Vertex Presents New Data on the Benefits of ALYFTREK

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store